Phase 2
once weekly, injection
GLP-1 RA · Zealand Pharma
Disease Pipeline Tools Obesity
Obesity
Programs, trials, and reported weight change for obesity and overweight.
Obesity pipeline
Programs by company or class, across phase, filing, approval, and a stop.
Phase 1 included.
Clear filters94 of 94 programs on this matrix
| Phase 1 | Phase 2 | Phase 3 | Filed | Approved | Discontinued | Stage n/r | |
|---|---|---|---|---|---|---|---|
| GLP-1 RA17 programs | Phase 2 once weekly, injection GLP-1 RA · Zealand Pharma Phase 2 daily, oral and injection GLP-1 RA · Pfizer | Registry, Jun 30, 2027 every 4 weeks, injection GLP-1 RA · Gan & Lee Pharmaceuticals Phase 3 once weekly, injection GLP-1 RA · Company n/r Registry, Jan 5, 2027 once weekly, oral and injection GLP-1 RA · Hangzhou Sciwind Biosciences Co Registry, Nov 30, 2026 once weekly, injection GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co Phase 3 twice daily, oral and injection GLP-1 RA · AstraZeneca Phase 3 once daily, oral GLP-1 RA · Huadong Medicine Phase 3 once daily, oral and injection GLP-1 RA · Sanofi Registry, Dec 31, 2026 once weekly, oral and injection GLP-1 RA · Innovent Registry, Feb 22, 2028 once daily, oral GLP-1 RA · Novo Nordisk Phase 3 once weekly GLP-1 RA · Roche Phase 3 once weekly, injection GLP-1 RA · CSPC Baike (Shandong) Biopharmaceutical Co Phase 2/3 weekly, oral and injection GLP-1 RA · Shanghai Yinnuo Pharmaceutical Technology Co. | Registry, Sep 6, 2028 once weekly, injection and tablet GLP-1 RA · Novo Nordisk Approved once daily, oral and injection GLP-1 RA · Novo Nordisk | Stage n/r once weekly, injection GLP-1 RA · Company n/r | |||
| GLP-1/GIP7 programs | Registry, Jul 2027 once weekly, subcutaneous GLP-1/GIP · Viking Therapeutics Phase 3 once daily, oral GLP-1/GIP · Viking Therapeutics Registry, Feb 28, 2027 once weekly, oral and injection GLP-1/GIP · BrightGene Bio-Medical Technology Co Registry, Nov 12, 2027 once weekly, injection GLP-1/GIP · Roche Registry, Dec 2026 once weekly, injection GLP-1/GIP · Huadong Medicine Registry, Oct 31, 2027 once weekly, oral and injection GLP-1/GIP · Fujian Shengdi Pharmaceutical Co | Registry, Jan 2027 once weekly, subcutaneous GLP-1/GIP · Eli Lilly | |||||
| GLP-1/glucagon4 programs | Phase 1 once daily, injection GLP-1/glucagon · AstraZeneca Phase 1 oral and injection GLP-1/glucagon · Merck | Phase 2 once weekly GLP-1/glucagon · Altimmune | Registry, Dec 8, 2026 once weekly, subcutaneous GLP-1/glucagon · Boehringer Ingelheim | ||||
| GIP/GLP-1/glucagon2 programs | Registry, Mar 14, 2027 once weekly, subcutaneous GIP/GLP-1/glucagon · Eli Lilly Registry, Jan 14, 2027 once weekly, oral and injection GIP/GLP-1/glucagon · The United Bio-Technology (Hengqin) Co | ||||||
| Amylin combo1 program | Registry, Mar 2027 once weekly, injection Amylin combo · Novo Nordisk | ||||||
| Oral small molecule7 programs | Phase 1 oral Oral small molecule · Pfizer | Phase 2 once daily Oral small molecule · Terns, Inc | Phase 3 once daily, oral Oral small molecule · Gasherbrum Bio, Inc Registry, Nov 18, 2026 once daily, oral Oral small molecule · AstraZeneca Phase 3 oral Oral small molecule · Shandong Suncadia Medicine Co Phase 3 once daily, oral Oral small molecule · Vincentage Pharma Co | Registry, Sep 6, 2027 once daily, tablet Oral small molecule · Eli Lilly | |||
| GLP-1 conjugate1 program | Registry, Jan 21, 2027 subcutaneous, subcutaneous GLP-1 conjugate · Amgen | ||||||
| Amylin6 programs | Phase 1/2 oral Amylin · Aconcagua Bio, Inc Phase 2 oral and injection Amylin · AbbVie | Registry, Mar 2028 once weekly, subcutaneous Amylin · Eli Lilly Registry, Oct 20, 2028 once weekly, injection Amylin · Roche Registry, Jan 26, 2027 once weekly, injection Amylin · Novo Nordisk Phase 2/3 weekly, oral and injection Amylin · AstraZeneca | |||||
| Myostatin/activin3 programs | Phase 2 every 4 weeks, injection Myostatin/activin · Scholar Rock Registry, Dec 31, 2028 weekly, injection Myostatin/activin · Eli Lilly Phase 2 injection Myostatin/activin · Regeneron | ||||||
| MC4R1 program | Registry, Mar 13, 2027 once daily, injection MC4R · Rhythm | ||||||
| CB12 programs | Phase 2 once daily, oral CB1 · Inversago Pharma | Phase 3 once daily, oral CB1 · Sanofi | |||||
| Lipase inhibitor1 program | Approved once monthly, oral Lipase inhibitor · Empros Pharma AB | ||||||
| Opioid and antidepressant1 program | Registry, Dec 31, 2030 daily Opioid and antidepressant · Orexigen Therapeutics, Inc | ||||||
| Sympathomimetic combo1 program | Phase 3 once daily, oral and injection Sympathomimetic combo · VIVUS | ||||||
| Monoamine reuptake2 programs | Phase 2 daily Monoamine reuptake · NeuroSearch | Phase 3 once daily, oral Monoamine reuptake · Abbott | |||||
| SARM1 program | Phase 2 weekly, oral and injection SARM · Veru Inc | ||||||
| Class not reported34 programs | IND submission Dosing n/r Class not reported · Scohia Phase 1 oral Class not reported · Carmot Australia First Pty Ltd Phase 1 injection Class not reported · Eli Lilly Registry, Nov 9, 2026 injection Class not reported · NeuroBo Pharmaceuticals Inc Phase 1 injection Class not reported · Hanmi Phase 1 Dosing n/r Class not reported · Alizyme Phase 1 Dosing n/r Class not reported · Corbus Pharmaceuticals Phase 1 injection Class not reported · AbbVie | Registry, Nov 20, 2026 injection Class not reported · Skye Bioscience Registry, Feb 2027 Dosing n/r Class not reported · Arrowhead Phase 2 Dosing n/r Class not reported · Eli Lilly Phase 1/2 once weekly, injection Class not reported · PegBio Co Phase 2 weekly, oral Class not reported · Verdiva Bio Dev Limited Phase 2 once daily, injection Class not reported · Carmot Therapeutics, Inc Phase 1/2 every 4 weeks, injection Class not reported · Pfizer Phase 2 once weekly, oral and injection Class not reported · Novo Nordisk Phase 2 once daily, oral Class not reported · Pfizer Phase 2 daily, oral Class not reported · Rhythm Phase 2 once weekly, injection Class not reported · Biohaven Therapeutics Phase 2 once daily, oral Class not reported · Shionogi Phase 2 once weekly, injection Class not reported · Novo Nordisk Studied in NCT06299098 Dosing n/r Class not reported · Regeneron | Registry, Jun 12, 2028 once weekly, oral and injection Class not reported · Novo Nordisk Phase 3 weekly, injection Class not reported · Eli Lilly Phase 3 once daily, oral and injection Class not reported · Ascletis Pharma (China) Co Registry, Sep 21, 2027 once weekly, injection Class not reported · Pfizer Phase 3 once weekly, injection Class not reported · Huadong Medicine Phase 2/3 injection Class not reported · Company n/r Registry, Nov 13, 2026 once weekly, injection Class not reported · Regeneron Phase 3 once weekly, oral and injection Class not reported · Guangdong Raynovent Biotech Co Phase 3 once weekly, oral and injection Class not reported · GSK Phase 3 once weekly, oral and injection Class not reported · Sanofi Phase 3 once daily, oral and injection Class not reported · Hengrui Registry, May 4, 2027 weekly, oral and injection Class not reported · AstraZeneca | ||||
| MetAP2 inhibitor1 program | Phase 3 weekly, injection MetAP2 inhibitor · Zafgen | ||||||
| Serotonin agonist1 program | Phase 1/2 once monthly, oral and injection Serotonin agonist · Novo Nordisk | ||||||
| Small molecule1 program | Phase 3 oral Small molecule · MindRank AI Ltd |